PTSD is among the most treatment-resistant psychiatric conditions in clinical medicine — response rates to first-line pharmacological treatments hover around 50 percent, and full remission occurs in fewer than one in five patients receiving guideline-concordant care. For veterans, first responders, and civilians throughout the Toledo area and northwest Ohio who have carried the weight of trauma without finding adequate relief, the standard options have too often proven insufficient. At Awakenings by Northwest Ohio Ketamine, we offer IV ketamine as an off-label treatment option for PTSD that draws on a growing body of evidence and on the deep clinical expertise of our team — led by Dr. William James, MD — in precisely the type of medicine that ketamine demands.
Why PTSD Is So Difficult to Treat — and Why Ketamine Offers a Different Approach
PTSD involves a specific pattern of neurobiological disruption that distinguishes it from generalized anxiety and that helps explain why many standard treatments fall short. The condition is characterized by hyperreactivity in threat-processing circuits — particularly involving the amygdala — combined with impaired inhibitory control from the prefrontal cortex and disrupted fear extinction processes in the hippocampus. This neurobiological signature means that PTSD is not simply anxious thinking that can be resolved through cognitive reframing alone. The fear response system has been structurally recalibrated by trauma, and restoring it to a more adaptive state requires interventions that can influence these neural circuits at a biological level.
This is precisely where ketamine’s mechanism becomes clinically relevant. Ketamine acts as an NMDA receptor antagonist, and its effects on glutamate signaling drive rapid promotion of synaptogenesis — the formation of new synaptic connections — through downstream activation of BDNF, AMPA receptor activity, and mTOR signaling. This cascade of synaptogenic activity is directly relevant to the impaired fear extinction and synaptic loss seen in PTSD, and it may help explain why ketamine produces rapid changes in PTSD symptoms that slower-acting interventions do not. Research published in the Journal of Psychiatric Research found that a single IV ketamine infusion produced significant, rapid reductions in PTSD symptom severity scores in a sample of combat-related PTSD patients compared to midazolam control, with effects observed within 24 hours (Feder et al., 2014). A subsequent randomized controlled trial by Feder and colleagues in 2021 found that repeated IV ketamine infusions produced significantly greater reduction in PTSD symptom severity and higher rates of response and remission compared to midazolam control, with sustained effects at two-week follow-up.
These findings do not make ketamine a definitive cure for PTSD — results vary by individual, and it is important that patients understand that IV ketamine remains an off-label option without FDA approval for PTSD specifically. What the evidence does support is that for a population with limited effective options, ketamine offers a biologically coherent and clinically promising addition to the toolkit. To understand more about how ketamine works at a neurological level, see our overview of the science behind ketamine therapy and how it works in the brain.
What PTSD Treatment at Awakenings Involves
At Awakenings by Northwest Ohio Ketamine, PTSD treatment begins with a thorough clinical evaluation designed to assess candidacy, understand your specific presentation and history, and build a care plan that makes sense for you. Our multidisciplinary team includes Dr. William James, MD, whose anesthesiology background means ketamine is administered with a procedural expertise that matters when dosing, monitoring, and side effect management are involved; Dr. Nadeem Moghal, who brings fellowship-level pain management training from the Cleveland Clinic Foundation; and Ben Wagner, PMHNP-BC, a board-certified Psychiatric Mental Health Nurse Practitioner who holds the mental health dimension of each patient’s care within the same clinical team.
This multidisciplinary structure is not incidental — it is central to why our approach to PTSD is different from single-specialty clinics. PTSD frequently co-occurs with chronic pain, and the overlap between trauma and somatic pain experience is well-documented in the literature. Patients who come to Awakenings with PTSD and comorbid pain benefit from a team that holds both dimensions in view simultaneously, rather than requiring fragmented referrals to separate providers who may never communicate with each other. Learn more about our full team on our providers page.
The standard IV ketamine induction for PTSD involves six infusions over two to three weeks, consistent with protocols used in major clinical trials. Each infusion is typically 40 to 60 minutes at sub-anesthetic dosing, followed by a monitoring period. Patients are required to arrange transportation and should not drive on infusion days. During infusions, dissociative experiences — altered perception of time, visual distortions, feelings of detachment — may occur. These are expected, not dangerous, and our team is present throughout to provide monitoring and support.
Integration coaching at Awakenings is a core component of our PTSD protocol. The post-infusion window represents a period of heightened neuroplasticity during which patients may be more receptive to processing trauma narratives, establishing new behavioral patterns, and engaging with the psychological work of recovery. Research suggests that coupling ketamine with psychotherapy or integration support may enhance and sustain outcomes beyond what infusions alone produce. We structure integration coaching to meet patients where they are and to complement any psychotherapy they may be receiving outside of Awakenings.
Practical Considerations for PTSD Patients Beginning Ketamine Treatment
Patients with PTSD often approach their first consultation at Awakenings with a mix of hope and understandable caution — hope because conventional treatment has not been enough, and caution because they have learned to protect themselves from experiences that feel unpredictable or threatening. We want to be straightforward about both what ketamine can offer and what it cannot.
IV ketamine may produce rapid and meaningful reductions in intrusive thoughts, hypervigilance, and emotional reactivity in some PTSD patients — sometimes beginning within hours or days of the first infusion. In others, response is more gradual or partial. Not every patient responds, and we discuss this honestly before treatment begins. What we can offer at Awakenings is a thorough clinical evaluation, an evidence-informed treatment protocol, and a team with genuine expertise in both the pharmacological and psychiatric dimensions of this work. Results vary by individual, and we do not make promises about specific outcomes.
Hypervigilance and environmental sensitivity common in PTSD are also relevant to the infusion experience itself. We take time before each session to walk through what you will experience and to create an environment — including dimmed lighting, a reclining chair, and attentive clinical presence — that minimizes the sensory load during the infusion. Discuss with your provider before treatment begins what accommodations or preparation would make the experience feel as safe as possible for you. Our thoughtful approach to the infusion environment is described further on our set and setting page.
Frequently Asked Questions
Is IV ketamine for PTSD FDA-approved?
No. IV ketamine for PTSD is an off-label use of an FDA-approved anesthetic. This means that while ketamine has been approved by the FDA for anesthesia, its use for PTSD has not undergone the specific FDA approval process for that indication. Off-label prescribing is common in medicine, and there is a growing body of clinical evidence supporting ketamine’s use in PTSD. Patients should understand this distinction clearly before beginning treatment.
How soon might I notice changes in my PTSD symptoms?
Clinical trial data indicates that some patients experience significant reductions in PTSD symptom severity within 24 hours of the first infusion. However, results vary considerably — some patients notice changes gradually over the course of the induction series, and others do not respond. We monitor symptom changes throughout the induction series and discuss what we are observing at each visit.
Do I have to stop my current PTSD medications before starting ketamine?
Not necessarily, but some medications require evaluation before IV ketamine is initiated. Our clinical team reviews your full medication list before your first infusion and advises on any modifications needed. Do not change or stop any medications without discussing it with our team first.
What if ketamine makes my PTSD symptoms temporarily worse?
Dissociative experiences during infusions can occasionally surface traumatic material more vividly during or immediately after the infusion. This is one reason integration coaching is a core part of our PTSD protocol at Awakenings — it provides support for processing whatever arises. We monitor patient experience throughout and after each infusion, and we are available to discuss any concerning experiences between sessions. Our team is trained to handle the full range of clinical responses.
Can ketamine be used alongside EMDR or other trauma-focused therapy?
Yes — and this combination is something we actively encourage. Some early research and clinical experience suggests that the neuroplasticity window following ketamine infusions may enhance the effectiveness of trauma-focused psychotherapy by making fear memories more amenable to reprocessing. If you are working with a therapist who provides EMDR or cognitive processing therapy, we can coordinate the timing of infusions and therapy sessions to optimize this relationship. For a deeper look at how psychedelic-assisted approaches complement trauma therapy, see our post on how psychedelic-assisted therapy can aid in PTSD recovery.
Key Takeaways
- IV ketamine is an off-label treatment for PTSD supported by randomized controlled trial evidence showing rapid and significant reductions in PTSD symptom severity compared to control conditions.
- Ketamine’s mechanism — NMDA receptor antagonism and downstream promotion of synaptogenesis — directly targets the neurobiological disruptions underlying PTSD, including impaired fear extinction and synaptic loss.
- At Awakenings by Northwest Ohio Ketamine in Toledo, PTSD treatment is delivered by a multidisciplinary team that holds both psychiatric and pain dimensions in view, under the leadership of Dr. William James, MD.
- Integration coaching is a core component of the PTSD protocol at Awakenings, designed to support patients during the post-infusion neuroplasticity window.
- Results vary by individual; IV ketamine remains an off-label option, and not all patients respond. Discuss with your provider whether this treatment is appropriate for your specific clinical situation.
PTSD does not define the rest of your life — and for patients who have not found adequate relief through standard options, a different biological approach may be the thing that finally shifts the picture. At Awakenings by Northwest Ohio Ketamine in Toledo, we offer that approach within a clinical framework built around expertise, accountability, and whole-person care. Schedule a consultation to speak with our team about whether IV ketamine may be right for you.
About Dr. William James, MD
Dr. William James, MD, leads Awakenings by Northwest Ohio Ketamine in Toledo, OH, bringing a clinical background spanning anesthesiology and pain management to the treatment of chronic pain and mood disorders. The clinical team also includes Dr. Nadeem Moghal, who completed a fellowship at the Cleveland Clinic Foundation Pain Management Center, and Ben Wagner, PMHNP-BC, a board-certified Psychiatric Mental Health Nurse Practitioner — a multidisciplinary composition specifically designed to hold the pain, mood, cognitive, and functional dimensions of each patient’s condition in view simultaneously. Together, they approach chronic pain as a whole-person condition, integrating anesthesiology expertise with behavioral health in a way that most single-specialty practices cannot.
References
Feder, A., et al. (2014). Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder. JAMA Psychiatry. https://pubmed.ncbi.nlm.nih.gov/25075793/
Feder, A., et al. (2021). A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder. Nature Medicine. https://www.nature.com/articles/s41591-021-01422-6
National Center for PTSD, U.S. Department of Veterans Affairs. https://www.ptsd.va.gov/
International Society for Traumatic Stress Studies (ISTSS). https://istss.org/
Medical Disclaimer
The information in this blog post is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. IV ketamine for PTSD is an off-label use of a controlled substance and requires evaluation and supervision by a licensed and qualified medical provider. Individual results vary. Whether IV ketamine is appropriate for any specific patient requires a thorough clinical evaluation. If you are experiencing a mental health crisis or thoughts of self-harm, please call or text 988 to reach the Suicide and Crisis Lifeline or go to your nearest emergency room.